Themis Medicare Ltd

Themis Medicare Ltd

₹ 212 -0.31%
24 Apr 11:08 a.m.
About

Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]

Key Points

Product Portfolio
The company manufactures and markets bulk APIs of synthetic and biotech origin, bulk intermediates, and formulations. In the formulations segment, the company manufactures anti-TB, anti-malarial, anti-cholesterol, and pain management drugs. [1]
The company manufactures 190+ different drugs for ~20 different therapeutic areas. [2]

  • Market Cap 1,953 Cr.
  • Current Price 212
  • High / Low 266 / 131
  • Stock P/E 43.1
  • Book Value 39.6
  • Dividend Yield 0.23 %
  • ROCE 19.7 %
  • ROE 17.3 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 36.9% CAGR over last 5 years

Cons

  • Earnings include an other income of Rs.24.2 Cr.
  • Debtor days have increased from 122 to 149 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
65.52 61.77 112.50 107.39 94.92 79.80 94.44 91.00 88.78 80.10 96.65 104.78 82.51
50.28 49.52 72.03 83.93 77.62 65.39 74.07 69.66 73.51 69.62 74.91 92.37 74.46
Operating Profit 15.24 12.25 40.47 23.46 17.30 14.41 20.37 21.34 15.27 10.48 21.74 12.41 8.05
OPM % 23.26% 19.83% 35.97% 21.85% 18.23% 18.06% 21.57% 23.45% 17.20% 13.08% 22.49% 11.84% 9.76%
3.55 2.48 4.82 4.37 4.44 4.25 6.45 6.22 7.13 5.32 6.29 6.66 5.94
Interest 2.92 3.09 2.67 2.05 2.13 1.93 2.26 2.37 2.23 2.71 2.49 2.04 2.68
Depreciation 2.09 2.38 2.35 2.38 2.37 2.39 2.46 2.56 2.67 2.80 3.03 3.07 3.10
Profit before tax 13.78 9.26 40.27 23.40 17.24 14.34 22.10 22.63 17.50 10.29 22.51 13.96 8.21
Tax % 14.66% 12.96% 22.52% 17.65% 27.78% 30.61% 21.22% 21.43% 23.94% 18.37% 19.19% 18.91% 10.35%
11.76 8.05 31.20 19.28 12.46 9.95 17.40 17.78 13.31 8.41 18.19 11.32 7.37
EPS in Rs 1.28 0.88 3.39 2.10 1.35 1.08 1.89 1.93 1.45 0.91 1.98 1.23 0.80
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
158 174 195 202 232 217 210 184 202 231 395 354 364
171 157 171 184 194 184 184 181 166 181 299 287 311
Operating Profit -13 17 24 18 38 33 25 2 36 49 96 67 53
OPM % -8% 10% 12% 9% 16% 15% 12% 1% 18% 21% 24% 19% 14%
3 3 5 13 3 4 6 5 12 13 18 25 24
Interest 14 15 16 15 12 12 12 12 13 13 9 10 10
Depreciation 8 9 9 11 12 7 7 8 8 9 9 10 12
Profit before tax -31 -4 4 5 17 18 11 -13 27 41 95 73 55
Tax % -4% -56% 32% -20% 11% 9% 1% 15% 8% 14% 23% 22%
-32 -6 3 6 16 16 11 -11 25 36 73 57 45
EPS in Rs -4.03 -0.79 0.32 0.73 1.91 1.77 1.23 -1.17 2.70 3.88 7.92 6.18 4.92
Dividend Payout % -2% -11% 28% 25% 9% 0% 0% 0% 6% 11% 6% 8%
Compounded Sales Growth
10 Years: 7%
5 Years: 11%
3 Years: 21%
TTM: 3%
Compounded Profit Growth
10 Years: 27%
5 Years: 37%
3 Years: 30%
TTM: -23%
Stock Price CAGR
10 Years: 40%
5 Years: 50%
3 Years: 79%
1 Year: 47%
Return on Equity
10 Years: 15%
5 Years: 16%
3 Years: 21%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 8 8 8 8 9 9 9 9 9 9 9 9 9
Reserves 50 43 48 51 66 143 160 149 174 209 278 330 355
151 155 148 140 128 82 80 82 100 87 80 92 95
71 65 79 77 73 54 56 74 67 65 61 82 90
Total Liabilities 280 272 284 277 275 289 305 314 350 371 428 514 548
134 124 121 122 117 124 126 123 116 133 144 162 166
CWIP 7 11 12 4 6 9 2 2 8 2 3 3 3
Investments 1 4 4 5 6 23 24 27 35 45 56 70 80
139 134 147 146 146 133 153 162 191 191 225 279 300
Total Assets 280 272 284 277 275 289 305 314 350 371 428 514 548

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-14 4 8 19 26 -2 8 11 0 57 34 16
-12 -5 -7 -6 -7 -4 -0 -4 -5 -16 -16 -24
5 29 2 -18 -13 5 -9 -10 7 -26 -18 0
Net Cash Flow -21 29 4 -5 5 -0 -1 -3 2 16 1 -8

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 111 68 74 82 75 81 120 145 186 123 93 149
Inventory Days 174 246 280 246 243 250 253 287 315 272 150 213
Days Payable 217 232 240 237 145 163 156 187 171 143 79 123
Cash Conversion Cycle 68 82 114 91 172 168 216 244 330 251 164 239
Working Capital Days 110 87 81 78 64 74 131 132 176 152 124 176
ROCE % -8% 5% 10% 9% 15% 13% 10% -1% 15% 18% 30% 20%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
67.22% 67.18% 67.18% 67.18% 67.18% 67.17% 67.17% 67.16% 67.16% 67.16% 67.16% 67.15%
0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.06% 0.04% 0.05% 0.01% 0.03%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
32.77% 32.81% 32.81% 32.81% 32.81% 32.80% 32.78% 32.78% 32.80% 32.77% 32.82% 32.81%
No. of Shareholders 6,8226,5116,2125,8915,9156,1266,3625,9276,0076,97011,24411,295

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents